Abstract
Background: Oncotype DX assay can help a breast multidisciplinary team (MDT) decide if patients with early breast cancer will benefit from chemotherapy. The test costs around £2,500. National Institute for Health and Care Excellence (NICE) has issued guidance for use of Oncotype DX as an option to help MDTs decide whether to offer chemotherapy to patients. On average six chemotherapy sessions are needed for breast cancer (£4,000 per session). In our department this test is only offered to early breast cancer patients and our aim was to assess how it guided our MDT regarding chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
